The Phase 1/2 study, which evaluated 12 patients across four dose cohorts, demonstrated that the drug effectively targets multiple disease-related processes. Data analyzed through June 30, 2026, revealed that nine out of nine evaluable patients with essential thrombocythemia or polycythemia vera achieved significant platelet reductions, ranging from 36% to 91%. Notably, patients with extreme thrombocytosis saw marked improvements within 30 days of initiating treatment.
Jubilant Therapeutics Reports Positive Early Data for JBI-802 in MPN Trial
Jubilant Therapeutics has unveiled the first clinical evidence for JBI-802, a dual LSD1/HDAC6 inhibitor, showing rapid and sustained platelet reduction in patients with myeloproliferative neoplasms. Presented at the SOHO 2026 meeting, the findings suggest a new therapeutic pathway for managing chronic blood cancers characterized by overproduction of blood cells.
Dr. Sandra Aung, the company's Chief Development Officer, reported that the drug maintained a manageable safety profile across the trial. While one dose-limiting thrombocytopenia event occurred at the 20 mg level, it was successfully resolved through dose modification. No patients discontinued treatment due to adverse events, and several participants have remained on the therapy for over six months. The drug’s design—which features a short half-life—allows for flexible titration, a feature that CEO Daniel O'Connor believes could provide a distinct advantage for long-term patient care. The ongoing trial continues to monitor molecular outcomes and long-term efficacy as the company explores JBI-802’s potential as a first-in-class treatment for these complex malignancies.
Comments (0)
No comments yet. Be the first!